Vol 10, Supplement 3 (February 2018): Journal of Thoracic Disease (Immunotherapy in Lung Cancer)

Posted On 2018-05-10 15:49:47

Strategies to modulate the body’s innate and adaptive immunity to treat advanced stage cancer has taken central stage in the management of solid and hematologic malignancies. Agents targeting the programmed death-1 (PD-1) pathway in particular, have become established therapies for various types of cancer.

Read More>>